TZP-102: Preliminary Phase IIb data

Top-line data from a double-blind, international Phase IIb trial in 201 patients with Type I or II diabetes and a confirmed diagnosis of gastroparesis showed that once-daily 10 and 20 mg oral TZP-102 each missed the primary endpoint of reducing GSDD composite score from baseline during the last 2 weeks of the 12-week treatment period vs. placebo (1.7 and 1.43 points, respectively, vs. 1.46 points, p-values not disclosed). TZP-102 was well tolerated. Top-line data from the Phase IIb DIGEST trial evaluating thrice-daily 10 mg TZP-102 given before meals to treat diabetic gastroparesis are expected in 1H13. TZP-102 has Fast Track designation in the U.S. for the indication. ...